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Until recently, the radiation dose to patients undergoing the 90Y selective internal 
radiation treatment (SIRT) procedure is determined by applying the partition model 
to 99mTc MAA pretreatment scan. There can be great uncertainty in radiation dose 
calculated from this approach and we presented a method to compute the 3D dose 
distributions resulting from 90Y SIRT based on 90Y positron emission tomography 
(PET) imaging. Five 90Y SIRT treatments were retrospectively analyzed. After 
90Y SIRT, patients had 90Y PET/CT imaging within 6 hours of the procedure. To 
obtain the 3D dose distribution of the patients, their respective 90Y PET images 
were convolved with a Monte Carlo generated voxel dose kernel. The sensitivity 
of the PET/CT scanner for 90Y was determined through phantom studies. The 3D 
dose distributions were then presented in DICOM RT dose format. By applying 
the linear quadratic model to the dose data, we derived the biologically effective 
dose and dose equivalent to 2 Gy/fraction delivery, taking into account the spatial 
and temporal dose rate variations specific for SIRT. Based on this data, we intend 
to infer tumor control probability and risk of radiation induced liver injury from 
SIRT by comparison with established dose limits. For the five cases, the mean dose 
to target ranged from 51.7 ± 28.6 Gy to 163 ± 53.7 Gy. Due to the inhomogeneous 
nature of the dose distribution, the GTVs were not covered adequately, leading to 
very low values of tumor control probability. The mean dose to the normal liver 
ranged from 21.4 ± 30.7 to 36.7 ± 25.9 Gy. According to QUANTEC recommenda-
tion, a patient with primary liver cancer and a patient with metastatic liver cancer 
has more than 5% risk of radiotherapy-induced liver disease (RILD).
PACS number: 87.53.Bn
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I. InTroducTIon
Selective Internal Radiation Treatment (SIRT) is the delivery of radiation treatment via intra-
hepatic arterial administration of 90Y microspheres. 90Y SIRT is an emerging modality in the 
management of patients with inoperable primary and metastatic liver cancer. It is based on the 
unique pattern of hepatic blood flow by which the majority of the tumor blood supply is derived 
from the hepatic artery, whereas hepatic parenchymal blood flow largely comes from the portal 
vein. When 90Y microspheres are introduced through the hepatic artery, 90Y microspheres will 
preferentially localize in the peritumoral and intratumoral arterial vasculature, delivering high 
dose of radiation to the tumors. The use of 90Y microspheres for treatment of liver neoplasms 
has been around for some time; prospective clinical trials have shown encouraging response 
and survival data.(1) 
JournAL oF APPLIEd cLInIcAL MEdIcAL PHYSIcS, VoLuME 14, nuMBEr 5, 2013
212   212
213  ng et al.: SIrT dosimetry from 90Y PET imaging  213
Journal of Applied clinical Medical Physics, Vol. 14, no. 5, 2013
Until now, the radiation dose for the SIRT procedure was estimated by the partition method 
based on pretreatment 99mTc MAA diagnostic angiogram.(2,3) However, there are great uncertain-
ties associated with this approach. The reproducibility of catheter positioning during therapy is 
questionable and the particle size of 90Y microsphere is different from that of 99mTc MAA, so 
the distribution of 99mTc MAA may not truly correspond to that of 90Y microsphere. 
In radionuclide therapy, the absorbed dose is usually estimated, because in vivo dose mea-
surement is not feasible in clinical settings. However, without accurate patient dosimetry, it 
is impossible to establish fundamental dose-response relationship for treatment efficacy and 
toxicity. Also, it is difficult for different institutes to compare treatment results. For SIRT treat-
ments, there is great inhomogeneity of 90Y concentration within the patient’s body and, because 
of the short range of the 90Y beta particles, the total dose and dose rate vary spatially over the 
irradiated volume. The dose rate also changes temporally as the 90Y decays. The spatial and 
temporal variations of dose rate will have different radiobiological effect on the tumor and normal 
tissues. The partition method assumes a uniform distribution of 90Y microsphere, disregarding 
the spatial and temporal variation of the dose and dose rate. Consequently, the radiobiological 
effects specific to SIRT are ignored, and the partition method is at best a simplified picture for 
the patient dosimetry.
90Y has an internal pair production component with a branching ratio of 31.87 ± 0.47 × 10-6.(4) 
Recently, this pair production component of 90Y decay for PET imaging has been employed to 
evaluate the distribution of 90Y for patients treated with SIR-Spheres.(5) The image quality of 
90Y PET is superior to the traditional Bremsstrahlung SPECT and correlates well to the diag-
nostic 18FDG PET and CT scan. In this paper, we computed patient dose from 90Y SIR-Spheres 
based on high-quality 90Y PET images. This makes possible the calculation of accurate 3D 
physical dose distributions. 
Considering the radiobiological effect of varying dose rates, tumor control probability and 
normal liver dose constraints should not be directly applied to the physical dose data. We used 
the linear quadratic (LQ) model to convert the physical dose to the biologically effective dose 
(BED). The BED was then converted to dose equivalent to delivery at 2 Gy/fraction (EQ2), 
which is the typical dose per fraction used in conventional external beam radiation therapy and 
upon which published limits for tumor control and normal tissue complication are usually based. 
With EQ2, the application of dose limits to tumor control and normal tissue are meaningful.
 
II. MATErIALS And METHodS
A.  Absorbed dose from 99mTc MAA scintigraphy
From January 2011 to March 2012, five patients (all male, aged 45–78 years) who received 
SIRT had subsequent 90Y PET scan in our institute. Three patients had inoperable hepatocellular 
carcinoma, the other two (patients 1 and 3) had inoperable metastatic liver cancer from primary 
colorectal cancer. All patients met the manufacturer’s assessment criteria for SIRT. Diagnostic 
whole body 18FDG PET/CT was done to assess the tumor extent and target localization. Prior 
to SIRT, arteriography, followed by 99mTc-labeled MAA scintigraphy, was performed on all 
patients to assess the hepatic arterial vasculature and also for hepatopulmonary shunt fraction 
calculation. It also detected any gastrointestinal reflux, if present. Whole body anterior and 
posterior planar images of the chest and abdomen were taken after infusion of 4 mCi of 99mTc 
MAA. Based on the 99mTc MAA distribution, absorbed dose was calculated with the partition 
method. The tumor absorbed dose, Dt, and normal liver absorbed dose, Dl, can be calculated 
from Eq. (1) and (2):(2)
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Here, A is the administered activity, M is the mass of the liver, Mt is the mass of tumor, and r 
is the tumor/liver activity uptake ratio determined from the scintigraphy. The tumor/liver activity 
uptake ratio, r, was calculated as (counts from tumor ROI)/(counts from normal liver ROI).
 
B.  calibration of PET/cT scanner for 90Y
To obtain the activity concentration of 90Y within the patients’ bodies, sensitivity of the PET 
scanner for 90Y was determined. Calibration of the PET/CT scanner for the 90Y isotope was 
performed with a rectangular phantom containing four spherical inserts containing 90Y solu-
tion in a cold background. 90Y solution was used instead of 90Y SIR-Spheres because the SIRT 
spheres tend to settle over time during imaging, resulting in an uneven distribution of 90Y 
within the spherical inserts. This could affect calibration accuracy. The inserts were filled with 
a nominal activity concentration of 2.996 MBq/ml of 90Y. The volume of the spheres ranged 
from 0.22 cm3 to 65.45 cm3, whereas the background volume was 8.26 liters. (See Fig. 1 for 
the PET/CT image of the calibration phantom.)
c.  dosimetry from 90Y PET/cT imaging
90Y PET/CT imaging was performed with GE Discovery STE PET/CT scanner (GE Healthcare, 
Waukesha, WI) within 6 hours of the SIRT procedure. Attenuation corrected 90Y PET images 
were collected at two bed positions 30 minutes each, covering the whole liver and lung base. 
For a known activity distribution in a homogeneous tissue of infinite extend, the spatial dose 
distribution can be determined by convolving the nuclide concentration (from the PET images 
in our case) with the dose point kernel, described in the following:(6)
 D• (r) A(r)     k(r)  (3)
Here D• (r) is the absorbed dose rate at point r, A(r) is the cumulative activity at point r, and 
k(r) is the dose point kernel. The Medical Internal Radiation Dose (MIRD) Committee calcu-
lated S values at the voxel level for several relevant radionuclides using EGS4.(7) In this study, 
Fig. 1. PET/CT image (a) of the calibration phantom. Variation (b) of the observed mean activity concentration for each 
spherical insert with the volume of the inserts.
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we used the published S values presented in MIRD Pamphlet 17(7) of 6 mm voxels for 90Y in 
a homogeneous medium.
Based on the calibration, the observed count rate for each voxel on the PET images was 
converted to the activity concentration for the 90Y distribution. The voxel size of the PET 
images was 5.47 × 5.47 × 3.27 mm3, therefore the 6 mm voxel point dose kernel from Bolch et 
al.(7) was first resampled to voxel size equivalent to the PET image voxel size for convolution. 
Figure 2 shows the two-dimensional representation of the resampled voxel point dose kernel 
which was subsequently convolved with the PET images to compute the instantaneous dose 
rate. The three-dimensional convolution was done in MATLAB (The MathWorks, Natick, MA; 
www.MathWorks.com). The resultant values were again resampled to voxel size of 2.5 × 2.5 × 
2.5 mm3 to match the voxel size of the CT images. Then by integrating the decaying dose rate 
to infinity, we obtained the total dose delivered to each voxel. DICOM-RT dose files were 
generated corresponding to the dose values. (See Fig. 3 for the dose distribution (Fig. 3(a)) and 
90Y PET/CT image (Fig. 3(b)) of patient 1).
For DVH computation, the target and organ at risk need to be localized. For each patient, 
the liver was localized on the 90Y PET/CT images. The target was localized on the diagnos-
tic 18FDG PET/CT images by radiation oncologists. The diagnostic 18FDG PET/CT images 
were registered to the 90Y PET/CT images and target copied to the 90Y PET/CT images for 
DVH computation.
Fig. 2. Resampled voxel dose kernel to match the voxel size of the PET images.
Fig. 3. 90Y PET image (a) 5 hours after treatment. Red contours indicate position of the target as localized by radiation 
oncologist based on diagnostic 18FDG PET/CT. 90Y is localized in the left lobe of the liver; very little activity is seen in 
the lung base. 90Y PET-based isodose map (b) from PET image of (a).
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d.   computation of biologically effective dose and dose equivalent to 2 Gy per 
fraction delivery
Once injected into the hepatic artery, the microspheres are distributed preferentially in the 
tumor areas, being trapped within the tumor microvasculature. There is very little biological 
clearance and 90Y decays with its physical half-life of 2.67 days. The 90Y microspheres become 
permanent implants. There are two considerations in applying the physical dose calculated 
from above to assess tumor control and the risk of radiotherapy-induced liver disease (RILD). 
Firstly, the delivery dose rate is changing, starting at maximum at the embolization procedure 
(can reach 4 Gy per hour for our group of patients), exponentially dropping to almost zero in ten 
half-lives. Secondly, the total dose and the dose rate are inhomogeneous throughout the target 
volume and organ-at-risk (OAR) volume. Thus the biological effect of the dose is also varying 
throughout the target volume and the OAR. It will be incorrect to compare the physical dose 
computed from the 90Y PET images directly with published data for tumor control and risk of 
RILD, when published data for radiation dose of tumor control and radiation-associated injury is 
often derived from external beam therapy data, most likely in fractionation of 2Gy/fraction.
The biologically effective dose (BED) is defined in terms of both physical and radiobiologi-
cal parameters, and is a measure of the total amount of lethal damage sustained by a specific 
tissue. The BED is obtained by multiplying the total physical dose with a modifying factor 
which takes into account the physical aspects of dose delivery (dose rate, dose per fraction). For 
a permanent implant delivering an initial dose rate of Ro, and involving a nuclide with decay 
constant λ, Eq. (4) gives the BED.(8) Here μ is the time constant for sublethal damage repair.(9) 
Since the 90Y microspheres are trapped in the capillary bed, there is virtually no biological 
clearance and 90Y decays with its physical half-life of 2.67 days, λ = 0.2596 d-1. μ = log2/T1/2 
is the repair constant for the repair of sublethal damage. Repair T1/2 for tumors and normal 
tissues are less well established than α/β, and from Gerbaulet et al.,(10) T1/2 = 30 min to 1 h 
for early-reacting normal tissues and tumors, and T1/2 = 1.5 h for late-reacting normal tissues. 






The initial dose rate Ro is given by total dose divided by the decay constant λ. 
Making use of this equation and the differential dose-volume histogram (dDVH), we con-
verted the physical dose dDVH to the BED dDVH. Then the BED dDVH was converted to 
equivalent doses as if given as fractionated irradiation at 2Gy/fraction by Eq. (5). Here we were 







where nd is the total dose corresponding to dose delivered at d = 2 Gy fractions. We denoted 
this dose as EQ2.
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E.  computation of tumor control probability
To calculate the overall tumor control probability based on the differential volume histogram, 
for each dose bin of the dDVH, of volume Vi receiving a dose Di, with clonogenic density ρi, 
the tumor control probability can be written as:(11)
 TCPi exp[ iViexp( Di)]  (6)
Here, α is the sensitivity of the tumor cells to radiation.





TCP ∏i[exp iViexp( Di)] 
         (7)
In Eq. (7), α equals to 0.33 Gy-1,(12) and we assumed α value is constant (all the tumor cells 




Sensitivity of our PET scanner for the 90Y isotope was determined by phantom study. Figure 1(a) 
shows the calibration phantom and Fig. 1(b) is the variation of the observed mean activity 
concentration for each spherical insert with the volume of the inserts. The quality of the PET/
CT image of the phantom was excellent, even the 0.22 cm3 sphere was visible. Each sphere 
was contoured and average activity concentration determined. The average activity concentra-
tions were plotted against the volume of spheres and result showed in Fig. 1(b). The dotted line 
showed the fitted data. Sensitivity of our PET scanner was found to be 0.32 cps/MBq. 
From December 2010 to March 2012, five patients had SIRT treatment in our institution 
with 90Y PET imaging done within 6 hours after SIRT. Patients 2 and 3 suffered from meta-
static liver cancer, patients 1, 4, and 5 had hepatocellular carcinoma. Figure 3(a) shows the 90Y 
PET image of patient 1 who suffered from inoperable multifocal hepatocarcinoma. 1.3 GBq 
of 90Y SIR-Spheres (SIRTeX Medical Limited, Sydney, Australia) was administered via a Fr3 
Progreat microcatheter (Terumo Medical Corp., Somerset, NJ) inserted into Fr5 Yashiro catheter 
(Terumo Medical Corp.) at the hepatic proper artery. Then 90Y PET imaging was performed 
5 hours afterwards. PET images showed the presence of hot spots in areas close to or within the 
target delineated by the radiation oncologist on the diagnostic 18FDG PET/CT images. Based 
on the 90Y PET images, the dose to the patients was computed. Figure 3(b) shows the resultant 
isodose distribution. For this patient, the mean dose to the target and normal liver was 112.5 ± 
47.6 Gy and 25.8 ± 28.1 Gy, respectively.
For the five patients, we also computed the dose to target and dose to normal liver based 
on the partition method using Eqs. (1) and (2). Figure 4 shows a comparison of the dose cal-
culated from the partition method and 90Y PET-based patient dosimetry for these five patients. 
Based on the differential dose-volume histograms for target and normal liver and using 
Eqs. (4) and (5), the BED DVH and the EQ2 DVH were computed. Figure 5 shows the DVHs 
of target and normal liver for patient 1. Table 1 shows the dose to target and normal liver for 
all the patients.
Using Eq. (7), we tried to compute the TCP for the five patients. A MATLAB program was 
written to do the computation based on the dDVHs. However, due to the inhomogeneous nature 
of SIRT, substantial cold spots were found in the target of all the patients and the calculated 
TCP were effectively zero for all the patients.
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Fig. 4. Comparison of dose computed from partition method and 90Y PET dosimetry for target and normal liver for the 
five patients in this study. Administered activity of 90Y is shown in the boxes.
Fig. 5. Cumulative DVH for various dose quantities of target and normal liver. The fraction of target volume receiving 
a higher dose is greater for EQ2 than the physical dose (see arrow), while for the healthy liver, the physical DVH and 
EQ2 DVH are very similar.
Table 1. Absorbed dose data for the five patients.
 Mean Dose to Target Mean Dose to Normal Liver
  Inj. Act. Target Vol 90Y PET BED10 EQ2 Vol 
90Y PET BED2.5 EQ2
 Patient (GBq) (cm3) (Gy) (Gy) (Gy) (cm3) (Gy) (Gy) (Gy)
 1 1.3 60.7 112.5 139.3 116.1 1540.7 25.8 38.8 21.5
 2 1.1 75.7 114.4 140.3 116.9 1070.3 22.3 38.4 21.4
 3 1 350.7 56.1 62.0 51.7 1949.2 36.6 54.4 30.2
 4 1.2 85.3 122.7 151.7 126.4 1341.7 41.9 66.6 36.7
 5 1.2 51.6 152.9 195.6 163.0 1201.2 29.4 52.8 29.4
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IV. dIScuSSIon
In this work, we presented a method of patient dosimetry for the SIRT procedure based on 
90Y PET/CT imaging which is practicable in a clinical setting. 90Y PET is a reliable method 
for the assessment of SIR-Sphere distribution with superior image quality compared to 90Y 
Bremstrahlung scan. We computed the patients’ three-dimensional dose distributions based on 
these high-resolution PET images and represented in DICOM-RT dose file format. In addition, 
the CT images provide additional anatomical information so that dose to other structures can 
be computed as required.
Sensitivity of the PET scanner was determined through phantom study. Sensitivity of our 
PET scanner for 90Y was found to be 0.32 cps/MBq. Werner et al.(14) determined the sensitivity 
of 90Y for their Siemens Biograph 16 HiRez PET scanner at 40 min/bed to be 0.72 cps/MBq, 
which is comparable to our results. Several studies have used partition model based on 99mTc 
MAA scans to compute the dose to tumor and normal liver for the 90Y SIRT procedure.(2,13) 
These approaches assumed uniform distribution of activity within each partition and only give 
an estimate of the dose received in each compartment. One other study has used an approach 
similar to ours to calculate the radiation absorbed dose for 90Y SIRT of an HCC patient. Sarfaraz 
et al.(15) convolved the 99mTc MAA SPECT image with a Monte Carlo generated voxel dose 
kernel to compute the dose distribution from the 90Y spheres. However, dosimetry based on 
99mTc MAA SPECT imaging has two major drawbacks. First, the difference in particle size 
of 99mTc MAA from the 90Y microspheres (MAA particles have diameters in the range 15 to 
30 microns and a density of 1.3 g/cc, and SIR-Sphere microspheres have diameters of 35 ± 5 
microns and a density of 1.6 g/cc(16)), and thus the distributions of the two types of particles are 
not identical. Secondly, there is uncertainty arising from catheter placement for 99mTc MAA and 
90Y SIRT which are, in fact, two separate procedures. Our results showed large discrepancies 
between the doses calculated based on partition method and 90Y PET dosimetry, especially the 
dose to the target (difference ranged from -53.8% to +178.4%). For the tumor, partition method 
generally overestimated the dose. Other than the fundamental differences between these two 
dose calculation methods, the large discrepancy for target dose arises from inconsistency of 
target localization. The partition method relies on the accuracy of the tumor to liver uptake ratio, 
r. For our study, this ratio is determined from planar 99mTc MAA scintigraphy for which the 
tumor and liver were localized on the 2D images. On the other hand, the target volume for the 
90Y PET dosimetry is based on diagnostic 18FDG PET/CT. Disagreement of target localization 
between the two approaches is to be expected, resulting in considerable difference in dose to 
target for the two methods. 
The SIR-Spheres are classified by regulators as a brachytherapy medical device, and radi-
oembolization with SIR-Spheres is effectively permanent implant brachytherapy. As discussed 
above, there is great dose inhomogeneity due to the way the 90Y microspheres are introduced 
into the patient’s body, and also due to rapid dose falloff with distance from the sources. As 
90Y decays, the dose rate will also change with time. The spatial and temporal variation of 
dose rate will have varying radiobiological effects on tumor control and normal liver sparing. 
The effect of these variations cannot be reflected if only the physical dose is reported. Also, 
because of the dose gradient, each voxel of the target and healthy liver will be receiving a 
different total dose at a different time, varying dose rate. Applying the LQ model to the mean 
dose of the target or healthy liver to get the mean BED is oversimplification. Thus, we applied 
the LQ model to the differential dose-volume histogram, calculating the BED and EQ2 dose 
for each dose bin within which the dose and dose rate is relatively constant. This will give us 
the BED dDVH and EQ2 dDVH. It was based upon these results that we computed the mean 
BED and mean EQ2 dose to the target and normal liver for each patient. Table 1 shows the 
mean physical dose, BED, and EQ2 for the target and normal liver. For the five patients, the 
mean dose to the target ranged from 51.7 ± 28.6 to 163 ± 53.7 Gy. Due to the inhomogeneous 
nature of the dose distribution, there were significant geographic misses of the target, leading 
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to very low values of tumor control probability. On the other hand, dose to the normal liver 
ranged from 21.4 ± 30.7 to 36.7 ± 25.9 Gy. According to QUANTEC recommendation,(17)  a 
patient with primary liver cancer and  a patient with metastatic liver cancer has more than 5% 
risk of radiation induced liver disease.   
Based on the DICOM-RT dose file, it is also possible to compute the dose to other critical 
structures such as lung, stomach, and duodenum, to assess the risk of pneumonia or gastroduo-
denal ulcer, as long as these structures are contoured and DVH-computed.
Strigari et al.(18) reported a mean dose of 110 Gy to target for 73 patients treated at their 
center with 74% partial or complete response. The mean dose to target for our patients ranged 
from 51.7 ± 28.6 to 163 ± 53.7 Gy, with median dose equals to 114 Gy. This compares favor-
ably with the Strigari study. Patient #3 has a very low uptake of 90Y to the tumor and liver. He 
suffered from extensive liver metastasis from colon cancer and passed away from unrelated 
complications within one month of the SIRT therapy. Figure 6 shows the 90Y PET and dose 
distribution for patient 3. We attempted to compute the TCP for our patients based on Ebert 
and Hoban.(11) Since there were significant mismatch between the planning target volume and 
the radioembolization zone, large areas of the PTV received very little dose, resulting in very 
low TCP values. It is unjustifiable to report the TCP at this stage.
 
V. concLuSIonS
We have presented a method of patient specific dosimetry based on 90Y PET/CT imaging 
which is feasible in a clinical setting. Due to inhomogeneity in dose and dose rate from 90Y 
throughout the irradiated volume, we propose reporting the BED and the EQ2 dose derived 
from the physical dose based on the LQ model. Further studies are required to compute the 
tumor control probability based on the dose distribution. Also a phantom study is needed to 
validate the dose computation.
 
Fig. 6. 90Y PET image (top row) 5 hours after treatment for patient 3. There was very little uptake over the whole liver. 
90Y PET based isodose map (bottom row) from PET image.
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